Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could outshine standard tumor measurements to predict survival

NCT ID NCT07685548

Knowledge-focused Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 past patients and enroll around 120 new participants with solid tumors who are receiving non-surgical treatment. The goal is to improve how doctors evaluate whether a treatment is working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI approach could provide a more accurate way to predict survival and guide treatment decisions for people with solid tumors.
What could go wrong
This is an observational study, not a treatment trial. The AI method may not prove better than current standards, and results may not apply to all tumor types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This multi-center retrospective-prospective cohort study includes adult patients (≥18 years) with radiologically or pathologically confirmed solid tumors who have received or are receiving non-surgical treatment. The retrospective cohort comprises approximately 6,000 patients treated between January 2015 and December 2025, with complete imaging, clinical, laboratory, and molecular data from multiple centers across China. The prospective cohort consists of approximately 120 patients consecutively enrolled from 2026 onward, with data collected in real-world clinical settings. Participants are excluded if imaging quality is insufficient for AI-based analysis, key clinical or follow-up data are missing, or they have concurrent malignancies that cannot be distinguished from the primary tumor. The study population reflects the diversity of solid tumor types and treatment patterns in routine clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, any sex. 2. Radiologically or pathologically confirmed diagnosis of solid tumor. 3. Received non-surgical treatment with a clearly defined treatment start date. 4. Availability of baseline and at least one follow-up imaging study (CT/MRI) of sufficient quality for AI-based segmentation and volumetric analysis. 5. Availability of key clinical data and follow-up outcome information. 6. For retrospective cohort: prior signed informed consent for biobank donation, agreeing to donate samples and data for medical research. 7. For prospective cohort: planned to receive or currently receiving non-surgical treatment, and able to provide written informed consent. Exclusion Criteria: 1. Imaging data incomplete or of insufficient quality for accurate segmentation or volumetric calculation. 2. Key clinical information or follow-up outcome data missing. 3. Treatment start or baseline time point cannot be clearly determined. 4. Concurrent other malignancy that cannot be distinguished from the primary study tumor. 5. Severe underlying diseases (e.g., cardiac, pulmonary, renal insufficiency) that may significantly affect survival outcome assessment. 6. Cognitive impairment or other conditions that prevent cooperation with study procedures. 7. For prospective cohort: expected inability to complete follow-up. 8. Other conditions judged by the investigator as unsuitable for study inclusion. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Neoplasms Solid tumor cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.